fbpx

Breaking News: Hydroxychloroquine Side Effects Potentially Mitigated by Transdermal Delivery

Codebase Investee has secured rights to develop a Transdermal Hydroxychloroquine Drug Delivery System to offer controlled, prescribed dosage mitigating side effects

Codebase Ventures Inc. (OTCQB: BKLLF) (CSE: CODE), an investment company, is pleased to expand upon its announcement of April 16th regarding its agreement to acquire a 49% interest in an arms-length private company with the rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ) to treat malaria, lupus and rheumatoid arthritis.

Hydroxychloroquine has been heavily publicized in relation to its potential treatment and prevention role with Covid-19, leading to instances of self medication, where “hydroxychloroquine can have dangerous side-effects if the dose is not carefully controlled.”1,2

  • In oral tablet form, hydroxychloroquine side effects include headache, dizziness, diarrhea, vomiting, blurred vision, and arrhythmia among others3
  • Transdermal delivery of hydroxychloroquine regulates dosage, improving patient compliance and outcomes4
  • Bypassing the GI tract mitigates gastrointestinal side effects
  • Transdermal delivery is more efficient, therefore requiring less of the active ingredient to be administered

The hydroxychloroquine transdermal drug delivery system to be developed by an investee company of Codebase is designed to control dosage and to deliver the prescribed amount of the drug over the prescribed time period without inconsistencies inherent in oral tablet delivery – the premise being that transdermal delivery can reduce and/or eliminate side effects associated with uncontrolled dosing.

Reformulation Research Laboratories Inc. (RRL), Code’s contract lab partners in the venture, have provided that transdermal delivery of hydroxychloroquine can result in improved well being for patients by providing constant drug levels, fewer side effects overall, highlighted by the fact unlike oral tablets, transdermal delivery bypasses the gastrointestinal tract which can eliminate side effects from that route such as nausea. In addition, limitations on bioavailability and metabolism of the active ingredient when taken orally require dosages to be higher than what is required for therapeutic results. Transdermal delivery is more efficient, and with greater bioavailability and therefore lower amounts of the active ingredient are required, which also can improve outcomes for patients.

The Company’s scientific expert has read and approved the scientific disclosures contained in the press release. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 at this time. RRL is not making any express or implied claims that any of its products have the ability to deliver hydroxychloroquine through transdermal at this time.

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30089-8/fulltext

https://nationalpost.com/news/politics/canada-quietly-secured-order-for-5-millions-pills-of-anti-malaria-medication-eyed-as-potential-covid-19-treatment

https://www.healthline.com/health/hydroxychloroquine-oral-tablet

https://www.sciencedirect.com/topics/medicine-and-dentistry/transdermal-drug-administration

About Codebase Ventures Inc.

Codebase Ventures Inc. is an investment company, led by technology and business experts who invest early in great ideas in sectors that have significant upside, including the cannabis sector. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow’s standards with platforms, protocols, and innovations – not just products. We invest early, support those founders, take their ideas to market and work tirelessly to help them realize their vision.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For codebase ventures inc. financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.